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Abstract
Vaccines have been successfully used for prophylaxis of infectious diseases for a long 
time and in the last decades have inspired researchers to make products with similar 
immunological mechanisms for cancer immunotherapy, which has been developed rap-
idly into clinical applications and has shown remarkable therapeutic efficacy, as exempli-
fied by chimeric Ag receptor T cell (CAR-T cell) and immune checkpoint inhibitor-based 
therapies which can efficiently strengthen the body’s immune system to fight against 
cancer, but they are also expensive. Therefore, encouraged by recent success of cancer 
immunotherapy, scientists are actively developing the low-cost tumor Ag-based vac-
cines, which, however, usually exhibit weak immunostimulating effects and, therefore, 
are often formulated with nanoparticulate carriers to form a vaccine adjuvant-delivery 
system (VADS), which can not only enhance the efficacy but also mitigate the off-target 
toxicity associated with conventional anticancer vaccines. These nanoparticulate carrier-
based VADSs have demonstrated multiple functions, such as targetedly triggering 
Ag-presenting cells, reeducating tumor-associated macrophages (TAM) to function as 
tumor suppressor agent, and eliciting robust cytotoxic T lymphocytes (CTLs) to kill 
tumor cells. This chapter introduces multifunctional VADS that have been engineered 
with nanoparticulate carriers, including polymeric-, lipid-, metallic-, and cell-based 
nanoparticles, and used as an alternative to the existent tools for cancer immunotherapy.
Keywords: cancer immunotherapy, vaccine adjuvant-delivery system (VADS), 
immunoresponse, nanocarrier, cellular immunity, immune surveillance,  
danger-associated molecular pattern
1. Introduction
The huge success in vaccination against infectious diseases inspired researchers to explore 
the principles of immunotherapy for controlling tumor growth using host immune system, 
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which has been tried to be triggered with a variety of strategies, such as immune check-
point inhibitor- and engineered T cell-based therapies, to elicit antitumor immunity in the 
body and has shown great potential in treatment and prevention of recurrence of cancer, as 
exampled by recent striking outcomes of cancer immunotherapy in clinical applications [1, 
2]. From the overall view, current cancer immunotherapy is usually undertaken in two ways: 
establishment of systemic immunity through utilizing cytokines, vaccines, or adoptive cell 
transfer (ACT) and regulation of local immunosuppressive tumor microenvironment through 
utilizing small molecules and immune checkpoint inhibitors. Immune checkpoint therapy 
addresses regulatory pathways in preexisting Ag-specific T cells aiming at enhancing anti-
tumor immune responses, whereas self-sustaining systemic anticancer immunity proceeds 
with anticancer immune response, which is dictated by both vaccines and TME [3]. However, 
immune checkpoint inhibitors are mostly aimed at augmenting the potency of preexisting 
tumor-specific T cells and as such benefit only a portion of patients [2], while the strategies 
based on the engineered T cells involve complex bioengineering processes with almost an 
unacceptable cost and, sometimes, off-target severe toxicities [4]. These situations compel 
researchers to develop other anticancer tools, including, especially, the tumor Ag-containing 
vaccines, which trigger the immune system to establish anticancer immunity through sev-
eral crucial processes: release of Ags from tumor beds to be taken up by Ag-presenting cells 
(APCs) or delivery of Ags to APCs, APC activation for presentation of tumor Ags, priming 
and activation of T cells by activated APCs, migration and infiltration of effector T cells back 
to the tumor, and finally the recognition and killing of tumor cells by effector T cells, each of 
which, theoretically, can be targeted with various therapeutic approaches [5]. In particular, 
cancer vaccines that are designed for targeting early steps of Ag processing are potentially 
able to enhance both therapeutic and prophylactic efficacies against not only primary tumor 
but also inoperable metastasis or relapse and will therefore benefit a wide range of patients, 
especially the ones that lack sufficient levels of preexisting tumor-specific T cells and immune 
checkpoint-related molecules [6].
However, despite having in expectation tremendous therapeutic potential, cancer vaccines 
designed in conventional ways have been found elusive for successful treatment and eradica-
tion of tumors due to their weak immunogen insufficient to induce immune responses with 
conventional vaccination approaches. In addition, there are several other issues that may 
block the establishment of anticancer immunity, including degradation and rapid elimination 
of Ag, ineffective DCs uptake and Ag presentation, the suppression of T cell functions, and 
impairment of Ag presentation by the endoplasmic reticulum (ER) stress-driven lipid metab-
olism in DCs, thereby inhibiting protective T cell responses in cancer immunotherapy [7]. 
All of these highlight the need for developing new strategies to prepare cancer vaccines that 
can efficiently deliver tumor Ags and adjuvants to APCs and stimulate immune responses 
strong enough to kill tumor cells [8]. In this regard, NPs, such as liposomes, polymeric aggre-
gates, and inorganic NPs, when used as a vaccine carrier have proven to be able to enhance 
the accumulation in draining lymph nodes (dLNs) of immunostimulants and adjuvant Ags, 
which thereby approach and stimulate a large number of Ag-presenting cells (APCs) enriched 
in dLNs to initiate cellular immunity required for fighting against cancer [6]. Moreover, 
several decades of intensive investigation on different types of NPs for targeting delivery 
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of traditional chemotherapeutics to solid tumors provide basis of repurposing these NPs to 
target the immune system and offer new opportunities to tune immunity and elicit strong 
antitumoral immune responses for overcoming the major challenge to the clinical translation 
of cancer vaccines [9].
Actually, multifunctional NPs show numerous advantages over conventional therapeutics 
for cancer immunotherapy: (1) NPs with finely tuned size and a defined surface features can 
achieve targeting delivery to lymphoid tissues, while most NPs composed of biomaterials bear-
ing immune-stimulating properties may serve a dual role as a vaccine carrier and an adjuvant, 
thus forming a vaccine adjuvant-delivery system (VADS) to simplify the vaccine production 
[10–12]; (2) NPs carrying both tumor Ags and adjuvants can stably co-deliver vaccine compo-
nents to APCs [13, 14]; (3) NPs can also be to display Ags and co-stimulatory ligands to serve 
as artificial APC and potentiate T cell immune responses [15]; (4) VADSs can be formulated 
to trigger immunogenic cell death or target immune checkpoint molecules leading to antitu-
moral immune responses and reverse of immune suppression [16]; and (5) VADS can also be 
loaded with therapeutics to improve antitumoral efficacy of adoptive T cell therapy [17].
This chapter elaborates new developments in areas of cancer immunotherapy, highlighting 
the potential of the VADSs engineered with various types of NPs for developing vaccines that 
are explored for cancer immunotherapy.
2. Cancer immunity and immunosuppression
Vertebrates are protected by the immune system from pathogens such as viruses, bacteria, 
fungi, and parasites through immune responses which can be classified into two categories, 
namely, innate and adaptive processes thus to establish, respectively, two types of immunity: 
the innate immunity providing rapid defense against pathogens and the more comprehensive 
adaptive immunity, which is set up requiring process of pathogens by professional APCs 
for presentation of immunogenic Ags to T and B cells to sponsoring cellular and humoral 
immune responses. Professional APCs, including B cells and macrophages, as well as den-
dritic cells (DCs) which are considered as the most efficient APC population, have proven 
to play a pivotal role at the interface of innate and adaptive immune responses [18, 19]. To 
initiate immune responses, DCs take up and then process endogenous or exogenous Ags in 
the context of major histocompatibility complex (MHC) class I or II, followed by presentation 
of the MHC-I or -II/Ag peptide complex as the activation “signal 1”, respectively, to CD8+ 
and CD4+ T cells, which are activated requiring an additional “signal 2” induced by ligation 
of co-stimulatory markers CD80/86 on DCs with CD28 on T cells, as well as a T cell polarizing 
“signal 3” provided by cytokines, such as interleukins (ILs) and interferons (IFNs) secreted by 
DCs [6]. Although MHC-I is constitutively expressed by most mammalian cells, nonprofes-
sional APCs can never present “signals 2 and 3” to alert the immune system after invasion by 
pathogens, highlighting the Ag processing and presentation by APCs as a critical first step in 
sponsoring adaptive immune responses. In particular, DCs rather than other APCs prove to 
be able to process exogenous pathogens to activate CD8+ T cells via a unique process called 
cross-presentation, of which, though the exact mechanisms are still unclear, the vacuolar and 
Vaccines Developed for Cancer Immunotherapy
http://dx.doi.org/10.5772/intechopen.80889
49
cytosolic pathways have been identified to utilize endosomes and endoplasmic reticulum, 
respectively, to generate the MHC-I/Ag peptide complexes [20–22]. Notably, the endosome 
pathway in normal conditions is devoted to process the exogenous Ags to form the MHC-II/
Ag peptide complexes for activation of CD4+ T cells, although the abnormal increase in 
endosomal pH or occurrence of endosome breakup made purposely by artificial strategies is 
thought to prevent the protease-mediated degradation of Ags in endosomes, thus promoting 
cross-presentation [12, 23], and additionally, certain DC subsets such as tissue-resident CD8+ 
and migratory CD103+ DCs in mice and CD141+/BDCA-3+ DCs in humans were reported to 
be more efficient at Ag cross-presentation than other DC subtypes [24, 25].
After activation and differentiation from CD8+ T cells in lymphoid tissues, the matured 
Ag-specific cytotoxic CD8+ T lymphocytes (CTLs) enter the systemic circulation and patrol 
peripheral tissues in search of target cells, which display a specific Ag epitope in the context 
of MHC-I matching the Ag-specific T cell receptors (TCRs) on CTLs, which once identification 
of the target cells will secrete perforin and granzymes to lyse them and within minutes move 
on to kill the next target [26]. By contrast, CD4+ T cells mainly play a helper role of regulation 
of immune responses as manifested by the observations that after activation by MHC-II/Ag 
peptide complex presented by DCs, naïve CD4+ T cells differentiate into four distinctive sub-
types depending on the polarizing cytokines [27]. Type 1 helper T cells (Th1) induced by IL-12 
secrete IL-2 and IFN-γ to promote CD8+ T cell responses; Th2 cells induced by IL-4 secrete IL-4 
and IL-5 and are involved in humoral immune responses; regulatory T cells (Tregs) induced by 
IL-2 and TGF-β (transforming growth factor beta) secrete TGF-β and IL-10 to suppress immune 
responses; and Th17 cells induced by TGF-β, IL-6, and IL-21 secrete IL-17 and IL-22 to break 
immune tolerance and possibly leading to autoimmunity [27, 28]. In addition, it is reported 
that CD4+ helper T cells are utilizing the expressed CD40L for feeding back to DCs to further 
amplify immune activation and aid in establishment of memory CD8+ T cell responses [29, 30].
To prevent cancerous occurrence, the immune system constantly implements a process 
referred to as immunosurveillance whereby to inhibit oncogenesis by actively identifying and 
eliminating tumor cells, which however, have also devised mechanisms to evade immune 
responses, including downregulation of tumor Ags and promotion of immunosuppression 
[31, 32]. In established tumor microenvironment, it is generally immunosuppressive due to 
upregulation or production of inhibitory molecules, such as TGF-β1, CXCL12, VEGF, ARG1 
(Arginase1), CCL18, iNOS (nitric oxide synthase), IL-10, IL-35, and galectin-1 by many types 
of cells, including cancer-associated fibroblasts, myeloid-derived suppressor cells, Tregs, and 
tumor-associated macrophages (TAMs), against T cells [33]. Also, activated T cells upregulate 
CTLA-4 (CTL-associated protein 4) which binds to co-stimulatory molecules on DCs with 
higher affinity than CD28, serves as a peripheral inhibitory signal to prevent over-reactivity of 
T cells, and dampens antitumor immune responses. Besides, tumor cells can also secrete cyto-
kines such as IL-10 and TGF-β, which both directly inhibit the proliferation of CTLs and drive 
the differentiation of Tregs to provide an additional source of immunosuppressive cytokines, 
while subsets of tumor cells highly express programmed death-ligand 1 (PD-L1) for binding 
to programmed death-1 (PD-1) on T cells and inhibiting their effector functions [34]. Thus, 
tumor cells can promote immunosuppressive tumor microenvironment and shield them-
selves from CTLs by hijacking normal negative feedback loops designed to guard against 
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excessive activation of T cell responses, suggesting that development of vaccines for cancer 
immonotherapy is still confronting a huge challenge arising from cancer immunosuppression.
3. NP entrapping various Ags for delivering cancer vaccines
Tumor Ags include mutated cell surface components, such as polysaccharides, peptides, onco-
proteins, and DNA and mRNA that encode those proteins, which as referred to subunit Ags, 
meanwhile tumor cell lysate and immunogenically dying tumor cells can also serve as the 
source of whole-cell Ags [6]. As key components utilized for formulating anticancer vaccines, 
subunit Ags have major advantages including defined chemical synthesis; ease of production; 
and for vaccine formulations, requiring, possibly, no Ag-processing by APCs and challenges 
including elicitation of humoral rather than cellular immune responses, poor delivery effi-
ciency, and in vivo stability. Whole-cell Ags have major advantages including broad-epitope 
immune responses, potential for “personalized” therapy, full preservation of tumor Ags and 
challenges including production requiring tissue biopsy, difficulty in manufacturing, loss 
of antigenicity during production, presence of self-Ags, and immunosuppressive molecules 
such as PD-L1. Notably some viruses, such as Epstein–Barr virus (EBV), human papilloma 
virus (HPV), and hepatitis B and C viruses, have proven to contribute to certain cancer-related 
development, and therefore, their virally gene encoded surface proteins may also serve as 
the potential target Ags to constitute the vaccines for cancer immunotherapy [35, 36]. Among 
different types of tumor Ags, oncoproteins, which are encoded by oncogenes involved in the 
regulation or synthesis of proteins linked to tumor cell growth and may also be either mutated 
or overexpressed normal or embryonic proteins from fetal development, are intensively inves-
tigated for cancer vaccines since they have a big potential in induction of broad-epitope CD8+ 
and CD4+ T cell responses. Notably, compared to full-length protein-based Ags that require 
cellular uptake and processing for presentation to T cells, peptide epitopes can directly bind 
to MHC molecules and thus directly activate T cells and, moreover, are more endurable to 
damages during the preparation and storage of vaccine products, thus, in line with these 
advantages, leading to many ongoing clinical trials on peptide-based cancer vaccines [37, 38].
However, poor immunogenicity and limited therapeutic efficacy are still big challenges in 
developing protein, especially, peptide Ag-based subunit vaccines that are designed for 
cancer immunotherapy; for example, in the case of melanoma, the identified Ags include 
β-catenin, survivin, tyrosinase, gp100, MAGE, melan-A (MART1), and NY-ESO-1, some of 
which, such as gp100 and MAGE-A3 peptides, when tested in clinical trials just showed only 
moderate or null therapeutic efficacy [39]. Grooming through clinical trials on peptide-based 
cancer vaccines, it may be safely concluded that therapeutic efficacy of subunit vaccines 
against cancer remains suboptimal [2], due to at least partially the fact that many tumor Ags 
evaluated in clinical trials are self-Ags which can hardly trigger the autoreactive T cells lead-
ing to immunotolerance [6]. These disappointed outcomes highlight that the conventional 
subunit vaccines should actually be formulated with innovative modalities, which may be 
an alternative promising strategy to further improve cancer immunotherapy, as evidenced 
by positive results obtained from pre- and clinical investigations carried out more recently 
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on cancer vaccines that were combined with other elements, such as potent adjuvants and 
NP-based VADSs. For example, in a preclinical study, researchers observed that, in a syn-
geneic mouse model of oral cancer comprised of mouse tonsil-derived epithelial cells stably 
expressing HPV-16 E6 and E7 genes along with H-ras oncogene (mEER), intranasal HPV 
E6/E7 peptide vaccination or single checkpoint antibodies failed to elicit responses in most 
mice; however, 4-1BB agonist antibody along with either CD40 agonist antibody or CTLA-4 
blockade eliminated the majority of established mEER tumors, and even produced a curative 
efficacy and a high safety profile against orally implanted mEER tumors [40]. For another 
example, in a phase II clinical trial, researchers performed immunotherapy with two peptide 
cancer vaccines in combination with intravesical bacillus Calmette-Guerin (BCG) for patients 
with non-muscle invasive bladder cancer (NMIBC) and demonstrated that this combinatory 
immunotherapy had good immunogenicity and safety and resulted in a 2 year RFS rate 74.0% 
in all patients, suggesting the cancer vaccines with a combinatory mode may provide benefit 
to patients for preventing recurrence of NMIBC [41].
These investigations showed that the conventional vaccines have limited capability to target 
delivery of tumor Ags and adjuvants to proper APC and intracellular compartments and 
may be renovated by the NP-based vaccine adjuvant-delivery systems (VADSs) which have 
already poised to address these challenges as described below.
4. NPs delivery of cancer vaccines
Cancer immunotherapy by vaccines depends on eliciting in patient the antitumor adaptive 
cellular immunity, which is, however, governed by potent Ag-presenting DCs able to activate 
CD8+ T cells and engender the Ag-specific CTLs. For this purpose, various immunotherapy 
strategies have been developed, including, in particular, using NP-based VADSs that are so 
elaborately designed as to promote APC cross-presentation of Ags and to deliver Ags and/or 
adjuvants targeting APCs, tissues, or organs such as dLNs, wherein APCs aggregate in large 
number ready for uptake of foreign substances, as can hardly be accomplished by soluble Ags 
or adjuvants alone [12].
4.1. NPs promoting Ag cross-presentation for delivering cancer vaccines
During an immune response, exogenous Ags are usually processed and presented via MHC-II 
by APCs to CD4+ T cells; however, tumor Ags engulfed by APCs require to be presented via 
MHC-I to induce production of Ag-specific CTLs, which are the main effector cells against 
tumor cells, thus precluding traditional methods from engineering cancer vaccines as they 
rely on soluble protein or peptide tumor Ags which often skew immune responses to CD4+ 
T cell responses while failing to induce robust CTL responses which are sufficient for can-
cer immunotherapy. Fortunately, it is disclosed that tumor Ags delivered by the elaborately 
designed NP-based multifunctional VADS able to promote lysosome escape, which is trans-
location of Ags from endosomes or phagosomes to cytosol avoiding Ag degradation within 
lysosomes, may regulate Ags to be reloaded to endoplasmic reticulum (ER)-attached MHC-I 
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for cross-presentation and favorably elicit CD8+ T cell responses [24]. As such, to engender 
Ag lysosome escape, great efforts have been focused on pH-sensitive delivery systems that 
can retain the loaded cargo under the physiological pH condition while triggering release of 
Ags and disruption of endocytic vacuoles at the acidic (below pH 6) endosomal microenvi-
ronment [42], as exemplified by a pH-sensitive liposomal VADS which is formulated with a 
dextran derivative and was shown to promote cytosolic delivery of Ags [43].
More recently, Wang and colleagues through fabricating two types of pH-sensitive multi-
functional liposomes, the mannosylated lipid A-liposomes (MLLs) and the stealth lipid 
A-liposomes (SLLs) both loaded with Ags and NH
4
HCO
3
, into microneedles prepared the 
proSLL/MLL-constituted microneedle array (proSMMA), which dissolved rapidly recovering 
the initial MLLs and SLLs upon rehydration [12]. Mice vaccinated with proSMMAs by vaginal 
mucosa patching elicited robust Ag-specific humoral as well as cellular immunity at both sys-
temic and mucosal levels, especially, in the reproductive and intestinal ducts. Further explo-
ration revealed that the Ags delivered by either liposomes were cross-presented for MHC-I 
displaying by APCs thanks to lysosome escape and reactive oxygen species stimulation, both 
of which occurred when lysosomal acidifying the liposome-released NH
4
HCO
3
 into CO
2
 and 
NH
4
+/NH
3
 to rupture lysosomes by gas expansion and to cause ROS production by excessive 
ammonia induction, resulting in a mixed Th1/Th2 type response which was also promoted by 
liposomal lipid A via activation of TLR4, indicating the proSMMAs a multifunctional VADS 
capable of engendering Ag lysosome escape to elicit robust humoral and cellular immunity 
against Ags and a promising platform for making both cancer and infection vaccines.
In addition, an alternative approach for evading lysosome degradation of Ag includes mul-
tifunctional VADS constituting of the oxidation-sensitive polymersomes that can respond to 
the oxidative environment of endosomes and deliver Ags and adjuvants to cellular cytosol 
for induction of cellular immune responses [44]. Notably, liposomes modified with a cell-
penetrating peptide octaarginine were also reported to be able to promote cross-presentation 
Ags and elicit production of anticancer CTLs, because the membrane-penetrating liposome 
enhanced proteolysis of the exogenous Ags by proteasomes and amino peptidases facilitating 
promoting the C-terminal trimming of antigen peptide and the production of mature MHC-I 
peptides [45]. Also, gold nanoparticles displaying tumor Ags were reported to enable efficient 
antigen delivery to dendritic cells and then activate the cells to facilitate cross-presentation, 
inducing Ag-specific CTL responses for effective cancer immunotherapy [46].
4.2. NPs targeting DC for delivering cancer vaccines
Recently, the approach based on amphiphilic polymer-Ag peptide conjugates through the 
conjugation of azide-functionalized Ag peptides to an alkyne-functionalized core via azide-
alkyne click chemistry has been employed for making nanovaccines against cancer. For 
example, by conjugation of the melanoma Ag peptide TRP2 and azido PEG mannose to the 
alkyne polymer, an anti-melanoma nanovaccine with the size of 10–30 nm was formed via 
self-assembly and was efficiently taken up by DCs [47]. In spite of poor immunogenicity, 
when given to model mice with B16-F10 melanoma tumors together with the adjuvant CpG, 
the adjuvanted TRP2-nanovaccines effectively suppressed the tumor growth and significantly 
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improved the survival of mice compared to the untreated group. Moon’s group engineered 
synthetic high density lipoprotein (sHDL) nanodiscs consisting of phospholipids, apolipopro-
tein A1 (Apo A1)-mimetic peptides and cholesterol-conjugated CpG (sHDL-Ag/CpG) with 
average diameter of 10 ± 0.5 nm, which were used as a multifunctional VADS able to target 
lymphoid organs, resulting in sustained Ag-presenting on DCs [48]. Moreover, the sHDL-
CpG-based VADS loaded with multiple Ags (MHC-I-restricted M27, MHC-II-restricted M30, 
and TRP2) in combination with anti-PD1/anti-CTLA4 antibodies successfully rejected B16-
F10 tumor from tumor-bearing mice.
Though targeting delivery with NPs is able to improve efficacy of cancer vaccines, tumor-
induced DC dysfunction arising from hyperactivity of signal transducer and activator of 
transcription 3 (STAT3) [49], which leads to less maturation in DCs with low responsive-
ness to pattern recognition receptor agonist (PRRa) stimulation [50], engenders another 
major huddle to developing effective vaccines for cancer immunotherapy. The NPs-based 
VADS was trialed in overcoming tumor-induced DCs dysfunction by Ma and colleagues 
through using poly(ethylene glycol)-b-poly(L-lysine)-b-poly(L-leucine) (PEG-PLL-
PLLeu) to form 120 nm-sized polypeptide micelles for encapsulation of polyI:C, STAT3 
siRNA, and OVA as a nanovaccine (PMP/OVA/siRNA), which proved able to decrease 
STAT3 expression and increase CD86 and CD40 expression as well as IL-12 production 
[51]. Moreover, PMP/OVA/siRNA nanovaccine could effectively increase mature DCs and 
decrease immunosuppressive cells in tumor draining lymph node, leading to antitumor 
immune response and prolonged survival, implying that novel VADSs designed for co-
delivery of immunopotentiator and immunosuppressive gene silencer may be one of 
potent strategies to improve antitumor immunity by modulating tumor-induced DCs in 
tumor microenvironment.
4.3. NPs targeting the lymph node for delivering cancer vaccines
Pattern recognition receptors (PRRs) are germline-encoded host sensors expressed mainly 
by cells of the innate immune system, such as MPs, (MPs) macrophages, monocytes, neutro-
phils, and epithelial cells, capable of detecting two classes of molecules: pathogen-associated 
molecular patterns (PAMPs), which are associated with microbial pathogens, and damage-
associated molecular patterns (DAMPs), which are associated with components of host’s cells 
that are released during cell damage or death [52]. PRRs play a crucial role in the proper 
function of the innate immune system evolved before other parts of the immune system, 
particularly before adaptive immunity, and mediate the initiation of Ag-specific adaptive 
immune response and release of inflammatory cytokines when they are activated by PRRas 
(PRR agonists), which are the microbe-specific molecules, including bacterial carbohydrates 
such as lipopolysaccharide (LPS) and mannose, bacterial peptides such as flagellin and 
microtubule elongation factors, peptidoglycans and lipoteichoic acids, nucleic acids such as 
bacterial or viral DNA and RNA, fungal glucans, and also chitin and thus are often used as 
vaccine adjuvants.
Since a fraction of PRRas such as LPS and unmethylated CpG ODN are soluble, preven-
tion of rapid diffusion of free PRRas into the systemic blood circulation is indispensable 
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for efficient targeting to professional APCs, which may be well obtained through for-
mulating into the NP-based VADSs. This has been accomplished by dextran-CpG-OVA 
conjugate that enhanced not only the CD8+ T cell responses but also improved the anti-
tumor immunotherapy through whole tumor cell vaccine. Recently, Liu and coworkers 
using reductive amination method conjugated oxidized dextran to amine-modified CpG 
ODN and demonstrated that the dextran-CpG conjugate with a hydrodynamic diameter 
of 6.5 nm was accumulated dLNs and was efficiently taken up by mouse DCs [53]. With 
the combination of OVA as a model Ag, dextran-CpG conjugate elicited production of 
Ag-specific CD8+ T cells for effective therapeutic benefits and in subcutaneously immu-
nized mice resulted in significant reduction of tumor growth and increased survival of 
mice.
To induce a potent MHC-I-restricted CTL response which is an essential component of the 
successful cancer immunotherapy treatment, Huang’s group formulated the mannosyl-
ated lipid-calcium-phosphate (MLCP) NPs as a new class of intracellular delivery systems 
for cytosol delivery into DCs of an exogenous Ag, p-Trp2 (the melanoma Ag Trp2 peptide 
derivative bearing two phosphor-serine residues) [54]. Compared with free Trp2 peptide/
CpG ODN, MLCP NPs encapsulation enhanced and prolonged the cargo deposit into the 
lymph nodes (LNs) and also resulted in superior inhibition of tumor growth in both B16F10 
subcutaneous and lung metastasis mouse models owing to induced IFN-γ production and a 
Trp2-specific CTL immune response. Thus, encapsulation of phospho-peptide Ags into LCP 
may be a promising strategy for enhancing the immunogenicity of poorly immunogenic self-
Ags for cancer therapy.
Recently, a nanovaccine, called AlbiVax that is assembled in vivo from endogenous albu-
min nanocarriers and exogenous molecular vaccines, which are chemically defined and 
relatively well suited to large-scale production including quality control and safety evalu-
ation, has been developed based on the albumin properties which are well known of not 
only being efficiently internalized by APCs via endocytosis to facilitate intracellular vac-
cine delivery for optimal Ag processing and presentation but also binding to a clinically 
practiced Evans blue (EB) [55]. AlbiVax was synthesized by conjugating thiol-modified 
vaccines and adjuvants, such as the 3′-end thiol-modified CpG and Ags (CSIINFEKL, 
Trp2, and Adpgk) modified with N-terminal cysteine, with maleimide-functionalized 
EB derivative which can tightly bind to human serum albumin. Further investigation 
revealed that, compared to benchmark incomplete Freund’s adjuvant (IFA), AlbiVax had 
a much high efficiency in co-delivery of CpG and Ags to LNs and in eliciting peripheral 
Ag-specific CD8+ CTLs with immune memory and specifically inhibited progression of 
established primary or metastatic EG7.OVA, B16F10, and MC38 tumors; but only in com-
bination with anti-PD-1 and/or Abraxane did AlbiVax eradicate most MC38 tumors. These 
outcomes indicate that as a novel type of VADS, the in vivo self-assembled molecular 
nanovaccines can not only enhance vaccine bioavailability in LNs but also bypass the 
complications, such as inefficient delivery, sequestering Ag determinant-specific T cells 
in the depots, and exhausting and depleting T cells, thereby preventing T cells from infil-
trating tumors and difficulty in large-scale production, which are often associated with 
conventional synthetic vaccines [56].
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4.4. NPs in combination for delivering cancer vaccines
The VADs based on various NPs that are engineered with different adjuvants such as PRRas 
and tumor Ags in combination for delivery of vaccines to the same immune cells have a 
great potential in provoking immune responses, generating increased duration and speed 
of immune response, regulating Ag-antibody response, and amplifying immunogenicity of 
weak Ags [12]. For example, it is reported that the application of poly(γ-glutamic acid)-based 
NPs for the delivery of model Ag (OVA) and toll-like receptor 3 (TLR3) agonist poly (I:C) 
(polyinosinic-polycytidylic acid) in targeting the LNs significantly enhanced the antitumor 
immunity against EG7-OVA (EL-4 thymoma cells transfected with chicken albumin cDNA) in 
tumor-bearing mice [57]. Recently, Molino et al. designed a biomimetic approach for eliciting 
antitumor responses through engineering the viral-mimicking protein NP vaccine, which is 
pyruvate dehydrogenase E2 protein NP (of 50 nm) conjugated to gp100 epitope (melanoma-
associated Ag) and CpG [58]. The CpG-gp-E2 NPs remarkably increased the proliferation of 
Ag-specific CD8+ T cells and production of IFN-γ and dramatically enhanced the population 
of CD8+ T cells in dLNs, resulting in the delayed onset of tumor growth in mice as well as 
elevated mouse survival, compared to control PBS-treated animals.
It should be pointed out that delivery of vaccine Ags and adjuvants to target tissues or cells by 
a VADS is also, to a great extent, dictated by NP properties, such as particle size and surface 
charge, which may be appropriately engineered for improving their delivery efficiency [59]. 
For example, the NP-based vaccines could be either delivered actively to the lymph nodes by 
DCs in target tissues or transported by the interstitial flow into the lymphatics, depending 
mainly on NP size and surface properties such as PEGylation and charge due to the upper limit 
of pore size of the lymphatic capillaries and cell uptake of NPs relevant to surface properties 
of both [12, 60]. Wang’s group engineered two types of multifunctional liposomes, the man-
nosylated lipid A-liposomes (MLLs) with a size of 200 nm and the stealth lipid A-liposomes 
(SLLs) of 50 nm, both of which were loaded with a model Ag and NH
4
HCO
3
 and fabricated 
into microneedles, forming the proSLL/MLL-constituted microneedle array (proSMMA) as 
a multifunctional VADS [12]. Mice vaccinated with proSMMAs by vaginal mucosa patch-
ing administration established robust Ag-specific humoral and cellular immunity at both 
systemic and mucosal levels, especially, in the reproductive and intestinal ducts, under the 
revealed mechanism that the MLLs reconstituted from the administered microneedles were 
mostly taken up by vaginal mucosa resident DCs, whereas the recovered SLLs trafficked 
directly to dLNs wherein they are to be picked up by macrophages, proving the size of NPs 
as an important parameter in controlling the in vivo fate of the delivered vaccines.
5. NPs for delivering DNA and mRNA vaccines
Using DNA and mRNA for intracellular production of oncogenic proteins or peptides 
as tumor Ags becomes an attractive strategy for developing cancer vaccines thanks to the 
advances in biotechnology which allows gene encoding proteins of interest to be easily 
manufactured in batch and be further modified with nucleic acid sequences that encode for 
proteins with immunostimulatory functions, for example, flagellin and a toll-like receptor 
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5 agonist (TLR5a). Unfortunately, previous clinical trials on DNA cancer vaccines, majority 
of which were administered as naked DNA via the intramuscular route, showed generally 
poor response rates, despite employment of viral vectors and electroporation able to improve 
the transfection of DNA vaccines, both of which cause safety and compliance concerns [61, 
62]. Alternatively, NPs engineered as a VADS for intracellular delivery of DNA and mRNA 
provide a promising strategy for developing nucleotide-based cancer vaccines and possess 
several advantages [6]: (1) synthetic material-constituted NPs are safer than viral vectors, (2) 
NPs can stabilize and protect gene therapeutics from nuclease-mediated degradation [63], (3) 
DNA- and RNA-loaded NPs can be administered by injection-free tools, such as microneedles 
for non-parenteral delivery [64], and (4) nanocarriers can be easily modified with targeting 
moieties, for example, mannose, to achieve DC-targeted delivery and transfection [14, 65].
It is reported that cationic liposomes and lipid nanoparticles containing mRNA coding for 
the tumor-associated Ags gp100 and TRP2 could induce a strong CD8+ T cell activation 
after a single immunization and treatment of B16F10 melanoma tumors with the mRNA-
carried cationic liposomes resulted in tumor shrinkage and extended the overall survival of 
the treated mice, all of which could be further increased by the combinatory incorporation 
of the adjuvant LPS, showing the cationic liposomes a promising vector for mRNA vaccine 
delivery that is capable of inducing a strong cytotoxic T cell response for cancer immuno-
therapy [66]. Nevertheless, nucleotide-based vaccines, including DNA and mRNA vaccines 
with their intracellular Ag synthesis, have been shown to be potent activators of a cytotoxic T 
cell response which is an important prerequisite for successful immunotherapy against many 
viral diseases and tumors [67], though intracellular delivery of mRNA vaccines to the cytosol 
of APCs is still not sufficiently well understood and remains somewhat a challenge to clinical 
translation for cancer immunotherapy [68].
6. NPs for overcoming immunosuppression
With great advances in immunology and oncology, several mechanisms, involving multiple 
immune components, have been identified to contribute to tumor immune escape, as sum-
marized by Chabanon and coauthors as these including [69]: (1) reduction of MHC-I molecule 
expression in malignant cells, resulting in decreased antigen presentation and consequently 
reduced detection by CTLs; (2) induction of immune cell apoptosis by cancer cells through 
the expression of death signals; (3) release of a variety of immune-modulatory molecules such 
as IL6 and IL10 by tumor cells in the microenvironment to induce immunosuppressive Tregs 
while inhibiting the activity of CTLs; (4) secretion of TGF-β, COX-2 (cyclooxygenase-2), and 
PGE2 (prostaglandin E2) by tumor cells inhibiting DC differentiation and maturation while 
favoring the establishment of an immunosuppressive tumor microenvironment; (5) upregu-
lated expression of immune checkpoint ligands to activate immune checkpoint receptors 
providing co-inhibitory signals to CD4+ and CD8+ T cells preventing them from building a 
specific antitumor immune response.
Among these elements involved in cancer resistance, immune checkpoints are regulators of 
the immune system to provide pathways crucial for self-tolerance and thus play an important 
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role both in the prevention of autoimmunity refraining the immune system from attacking 
cells indiscriminately under normal physiological conditions and in the regulation of immune 
reaction to avoid tissue damages during the pathogenic infection. Under normal conditions, 
immune checkpoints function via the interaction between a receptor expressed on T cells and 
its ligand located at the surface of APCs to generate a co-stimulatory signal, which triggers 
either the activation or inhibition of T cells. Presently, two major checkpoints have been clearly 
identified to regulate T cell activation: (i) the CD28/CTLA-4 axis, which activates T cells upon 
engagement of CD28 with CD80 and CD86, and conversely inhibits T cells when CTLA-4 is 
engaged and (ii) the PD-1 axis, which provides a strong inhibitory signal following binding 
of PD-L1 or PD-L2 to the PD-1 receptor [70]. Contrary to CTLA-4, PD-1 is thought to act pre-
dominantly in the tumor microenvironment, where PD-L1 is overexpressed by multiple cell 
types, including dendritic cells, M2 macrophages, and tumor-associated fibroblasts [71]. Thus, 
immune checkpoints and pathways, unfortunately, are also utilized by cancer cells as a key 
mechanisms to realize immune escape through upregulated expression of immune checkpoint 
ligands and as such deregulation of immune checkpoint signaling to suppress T cell activity 
in tumor microenvironment, a phenomenon that has been observed in multiple malignancies. 
Moreover, immune checkpoint molecules have been shown to promote the epithelial-mesen-
chymal transition of tumor cells and the acquisition of tumor-initiating potential and resistance 
to apoptosis and antitumor drugs, as well as the propensity to disseminate and metastasize, 
and thus have been increasingly considered as a crucial target for cancer immunotherapy given 
their potential for use in multiple types of cancers. Notably, as opposed to other immune-
based approaches developed to fight cancers, immune checkpoint blockers (ICBs) have dis-
played significant therapeutic successes in many solid tumors and hematologic malignancies, 
as exampled by several anti-PD-(L)1-based drugs, such as the anti-CTLA-4 ipilimumab (by 
Bristol-Myers Squibb), the anti-PD-1 pembrolizumab (by Merck), and the anti-PD-L1 atezoli-
zumab (by Genentech/Roche), durvalumab (by AstraZeneca/MedImmune), and avelumab (by 
Pfizer), all of which have already been approved for cancer immunotherapy [69].
However, with the current antibody-based immune checkpoint therapy, the nonspecific 
accumulation of antibody in the normal organs and tissues may ignite overreactive immune 
responses, which may even damage the body and cause severe side effects [72]; suggesting 
targeting delivery may provide beneficial effects even in the antibody-based immunotherapy. 
Recent studies have shown that a diverse set of NPs that have been engineered to improve 
delivery efficiency of immune checkpoint modulators which possess the potency in enhance-
ment of the anticancer efficacy of the immune checkpoint blockade-based immunotherapy. 
Using a common procedure of water-in-oil-in-water emulsion, Wang’s group formulated cat-
ionic NPs loaded with CTLA4 siRNA (siCTLA4) which was to modulate immune suppression 
mechanism [73]. The siCTLA4-NPs delivered siRNA into the T cells reducing mRNA and 
protein levels of CTLA4 upon the T cell activation in vitro and, when systemically given to 
mice, significantly increased the number of both CD4+ T cells and CD8+ T cells, whereas the 
number of CD4+ FOXP3+ regulatory T cells were decreased, resulting in the inhibited tumor 
growth and prolonged survival rate of B16 mouse melanoma model. PD-L1 is expressed on 
a variety of tumor cells, such as melanoma, NSCLC, ovarian cancer, head and neck cancer, 
B cell lymphoma, and thymic cancer and therefore is another attractive target for immune 
checkpoint modulation, which can be realized using tumor-targeted delivery system loaded 
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with relevant functional molecules. Yang et al. engineered folic acid-modified NPs with 
polyethyleneimine (PEI) derivatives and demonstrated that PD-L1 siRNA-loaded PEI NPs 
efficiently inhibited PD-L1 expression on SKOV-3-Luc tumor cells, resulting in sensitizing 
tumor cells to T cell killing in vitro [74]. Considering cancer recurrence after surgical resec-
tion remains still a significant challenge and platelets can accumulate in wound sites and 
interact with circulating tumor cells (CTCs) triggering inflammation and repair processes in 
the remaining tumor microenvironment, Gu’s group engineered the anti-PD-L1 antibody-
conjugated platelets (P-aPDL1) which were employed to reduce postsurgical tumor recur-
rence and metastasis [75]. In mouse models bearing partially removed primary melanomas 
(B16-F10) or 4T1 (triple-negative breast carcinomas), B16-F10 effectively released anti-PD-L1 
upon platelet activation by platelet-derived microparticles and remarkably prolonged overall 
mouse survival after surgery by reducing the risk of cancer regrowth and metastatic spread, 
suggesting engineered platelets an efficient VADS which can facilitate the delivery of the 
immunotherapeutic anti-PD-L1 to the surgical bed and target CTCs in the bloodstream to 
improve the objective response rate.
Summarily, the VADSs based on various NPs that are engineered to bear therapeutic func-
tions are promising in targeted delivery of the immunomodulatory agents to offset the immu-
nosuppressive effects generated in tumor microenvironment and to rehabilitate the defensive 
immunity, maximizing the efficacy of cancer immunotherapy while minimizing side effects.
7. Conclusions
In recent years various types of NPs have been designed as a VADS for delivery of vaccines 
that are aimed for cancer immunotherapies and have shown great promise in curing refractory 
tumors which can never be obtained by conventional clinical measures, such as chemothera-
peutics, surgery, and radiation. The NP-based cancer VADS possesses numerous advantages, 
including high safety profile and thus good compliance, high stability, diverse administration 
routes, and ease in modification with functional molecules as well as large-scale production, 
and bears also disadvantages including mainly relatively weak immunostimulatory capac-
ity and low intracellular especially intranuclear delivery efficiency, which may be hopefully 
overcome by elaborate design with adjuvants such as PRRas and multifunctional molecules. 
Nevertheless, the NP-based cancer VADS proves able to successfully elicit antitumor immu-
nity both in vitro and in vivo through, in particular, targeting APCs and draining lymph 
nodes, engendering lysosome escape, and modulating immunosuppression and represents 
new directions in developing efficient tools for cancer immunotherapy.
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